Mirova US’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$230M Sell
2,540,381
-86,934
-3% -$7.28M 2.47% 17
2026
Q1
$210M Sell
2,627,315
-111,756
-4% -$9.21M 2.39% 20
2025
Q4
$234M Sell
2,739,071
-83,021
-3% -$6.81M 2.34% 20
2025
Q3
$219M Sell
2,822,092
-109,205
-4% -$8.53M 2.22% 20
2025
Q2
$229M Buy
2,931,297
+1,054,301
+56% +$78.6M 2.37% 21
2025
Q1
$136M Buy
1,876,996
+67,774
+4% +$4.85M 1.62% 24
2024
Q4
$134M Sell
1,809,222
-53,910
-3% -$3.77M 1.61% 25
2024
Q3
$123M Buy
1,863,132
+1,000,066
+116% +$72.7M 1.41% 26
2024
Q2
$79.7M Buy
863,066
+17,365
+2% +$1.54M 0.99% 26
2024
Q1
$80.8M Sell
845,701
-14,699
-2% -$1.23M 1.09% 25
2023
Q4
$65.6M Sell
860,400
-5,150
-0.6% -$358K 0.99% 25
2023
Q3
$60M Buy
865,550
+33,641
+4% +$2.7M 1.02% 24
2023
Q2
$78.5M Buy
831,909
+19,816
+2% +$1.72M 1.31% 23
2023
Q1
$67.2M Buy
812,093
+9,211
+1% +$724K 1.22% 23
2022
Q4
$59.9M Buy
802,882
+19,423
+2% +$1.5M 1.2% 25
2022
Q3
$64.7M Buy
+783,459
New +$75.4M 1.51% 24

Other funds holding EW

Mirova US's EW Position: Q2 2026 in Review

Mirova US reduced its Edwards Lifesciences (EW) stake by 3.3% in Q2 2026, selling an estimated $7.28M and leaving 2,540,381 shares worth $230M. The position accounts for 2.47% of the portfolio, ranked #17.

Mirova US first reported a position in EW in Q3 2022 and has held it in 16 quarters since. The position peaked at $234M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Mirova US held 2,540,381 shares of Edwards Lifesciences worth $230M as of Q2 2026.
  • Mirova US sold 86,934 Edwards Lifesciences shares in Q2 2026, an estimated $7.28M.
  • Edwards Lifesciences made up 2.47% of Mirova US's portfolio in Q2 2026, its #17 holding.
  • Mirova US first reported a position in Edwards Lifesciences in Q3 2022 and has held it in 16 quarters since.
  • Mirova US's Edwards Lifesciences position peaked at $234M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Mirova US's 13F filing for Q2 2026, filed 14 Aug 2026.